Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811079 · ClinicalTrials.gov registry record · NA
The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer
A NA study, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
NCT04811079: Completed NA study, sponsored by Johnson & Johnson Vision Care.
NCT04811079 is a NA study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 53 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04811079, a NA study, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a 6-visit, single-center, non-dispensing, randomized, single-masked, 5×5 crossover study. Subjects will participate in 6 scheduled over the duration of approximately 10.5 months.
Primary Outcome
VPT will measured via the SAOPA instrument. VPT is the point at which a sensation of pain or discomfort occurs when the intensity of light is gradually increased from a low level. Subject's discomfort responses will be indicated via a button press. Testing is complete when 10 response reversals are acquired.
Interventions
- OTHER 419 nm Spectacle Filter
- OTHER 437 nm Spectacle Filter
- OTHER 456 nm Spectacle Filter
- OTHER 476 nm Spectacle Filter
- OTHER 373 nm Spectacle Filter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2022-05-16 |
| Phase | NA |
What the finished NCT04811079 record still lists
NCT04811079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which 419 nm Spectacle Filter is the first listed.
NCT04811079 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04811079 about?
NCT04811079 is a clinical study titled "The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer". This is a 6-visit, single-center, non-dispensing, randomized, single-masked, 5×5 crossover study. Subjects will participate in 6 scheduled over the duration of approximately 10.5 months.
What is the current status of trial NCT04811079?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2021-07-14. Estimated completion is 2022-05-16.
What interventions are being tested in trial NCT04811079?
The interventions under investigation include: 419 nm Spectacle Filter (OTHER), 437 nm Spectacle Filter (OTHER), 456 nm Spectacle Filter (OTHER), 476 nm Spectacle Filter (OTHER), 373 nm Spectacle Filter (OTHER).
Who is sponsoring clinical trial NCT04811079?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04811079's enrollment target sits among peer trials
53 1271st of 2000 higher than 729 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI